Introduction {#sec1-0300060518761304}
============

Breast cancer (BC) is the most prevalent cancer and a major cause of death among women worldwide. In Pakistan, the incidence of BC is approximately 34.6% in women.^[@bibr1-0300060518761304]^ Among risk factors, lifestyle, alcoholism, high birth weight, and abdominal adiposity intensify the risk of BC.^[@bibr2-0300060518761304][@bibr3-0300060518761304]--[@bibr4-0300060518761304]^ Diet may modify the incidence of BC,^[@bibr5-0300060518761304]^ although many dietary components such as vitamin D are categorized as "Limited or no conclusion."^[@bibr6-0300060518761304]^ Vitamin D plays a major role in mineral homeostasis;^[@bibr6-0300060518761304]^ however, evidence indicates that its deficiency exacerbates the risk of BC.^[@bibr7-0300060518761304],[@bibr8-0300060518761304]^ Moreover, higher vitamin D levels are weakly associated with the low BC risk".^[@bibr9-0300060518761304],[@bibr10-0300060518761304]^

Vitamin D derived from diet and sun exposure of the skin undergoes activation within the liver through 25 hydroxylation, and in the kidney through 1-α hydroxylation, to form 1,25(OH)2D3 (active vitamin D). The classical role of vitamin D is to regulate calcium and phosphate metabolism to maintain bone mineral density (BMD). However, there are wide ranges of nonclassical functions of vitamin D within the body. Vitamin D is activated by forming a complex with the vitamin D receptor (VDR) that is involved in the regulation of many target genes that contribute to cell differentiation, cell growth, programmed cell death, angiogenesis, inflammation, and immune responses.^[@bibr11-0300060518761304],[@bibr12-0300060518761304]^ Vitamin D, in concert with growth factors, arrests the cell cycle by preventing entry into S phase.^[@bibr13-0300060518761304]^ Vitamin D induces apoptosis through down-regulation of the antiapoptotic protein B-cell lymphoma 2 (BCL2),^[@bibr13-0300060518761304]^ inhibits the expression of P-cadherin^[@bibr14-0300060518761304]^ and increases the expression E-cadherin,^[@bibr15-0300060518761304]^ which may contribute to the anti-invasive or antimetastatic effects of vitamin D. Further, vitamin D induces the expression of the tumor suppressor BRCA1, because the binding sites for the vitamin D/VDR/retinoid X receptor heterodimer complex are present within the *BRCA1* promoter region.^[@bibr16-0300060518761304]^ Although VDR is present in many body tissues, including normal and cancerous breast tissues, its expression is low in mammary cancers cells,^[@bibr17-0300060518761304]^ which may be caused by variations in *VDR*.

There are many polymorphic regions in *VDR*, among which *Fok*1, *Bsm*1, *Apa*1, and *Taq*1 are the most extensively studied in American (Hispanic white, nonhispanic white, and Caucasian) and Asians (Iranian and Egyptian) populations.^[@bibr19-0300060518761304][@bibr20-0300060518761304][@bibr21-0300060518761304][@bibr22-0300060518761304][@bibr23-0300060518761304][@bibr24-0300060518761304]--[@bibr24-0300060518761304]^ Attention focuses on the role of single nucleotide polymorphisms (SNPs) in *VDR* that are associated with the development of a wide range of pathological conditions, including type 2 diabetes mellitus, prostate cancer, and BC^[@bibr18-0300060518761304][@bibr19-0300060518761304]--[@bibr20-0300060518761304]^. However, limited studies are available on the Pakistani population.^[@bibr25-0300060518761304]^ Studies of Jordanian populations reveal a statistically significant difference between *VDR Taq*1 variants and 25(OH)D among women with BC.^[@bibr21-0300060518761304]^ *Bsm*1 and *Cdx*2 polymorphisms are significantly associated with women with BC living in Southeastern Iran.^[@bibr20-0300060518761304]^ The *Fok1* SNP in BC plays a protective role, whereas the *Bsm1* SNP is not associated with BC among women living in the Iranian city of Urmia.^[@bibr22-0300060518761304]^ Among Egyptian women, the *Bsm*1 "B" allele and "Bb" variants of *VDR* may represent a risk factor for susceptibility to the development of BC.^[@bibr23-0300060518761304]^ In contrast, a meta-analysis shows no association of *VDR* SNPs (*Fok*1, *Bsm*1, *Taq*1, and *Apa*1) with risk of BC in a general population or in a Caucasian population.^[@bibr24-0300060518761304]^ Among Pakistanis who are BRCA1/2 non-carriers, the Bsm1 "b" allele is associated with an increased risk of BC".^[@bibr25-0300060518761304]^ Although the associations of *VDR Fok*1 and *Bsm*1 SNPs with the risk of BC have been investigated, no study, to our knowledge, investigated the relationship between the *VDR Tru*9I polymorphism and the premenopausal risk of BC. Therefore, the present study was designed detect an association between the novel low penetrance *VDR Tru*9I SNP and BC among premenopausal women of Pakistan.

Materials and methods {#sec2-0300060518761304}
=====================

Ethics statement {#sec3-0300060518761304}
----------------

The study was approved by the Bioethics Committee, Board of Advance Studies & Research, University of Karachi (ethics approval number \[10(27) 28032012\] and conducted in accordance with the Helsinki Declaration. Each subject provided written informed consent before providing a blood sample.

Study design and study population {#sec4-0300060518761304}
---------------------------------

The study included 228 patients with BC and 503 control subjects who were premenopausal ethnic Pakistanis aged 20--45 years. The sample size was calculated using OpenEpi (<http://www.openepi.com/Menu/OE_Menu.htm>) with 80% statistical power and 95% confidence intervals (95% CIs). Patients with BC, who were randomly selected from two tertiary hospitals in Sindh, Pakistan from 2012 to 2015, were histopathologically diagnosed. The medical information (types, grades, estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, and TNM classification) of patients with BC was obtained from histopathological reports and hospital records. All healthy volunteers were age-matched (1:2) to premenopausal healthy subjects acquired from the general population. Whole blood (3 mL) was collected from each subject. We used a self-structured questionnaire to acquire along with information about personal demographics, detailed history, and BC-related risk factors.

DNA isolation {#sec5-0300060518761304}
-------------

DNA was extracted using a DNA isolation kit (Gene JET Genomic DNA Purification Kit, Thermo Fisher Scientific Baltics UAB, and Vilnius, Lithuania) following the manufacturer's protocols. Samples were stored at --86°C.

Primer selection and genotyping {#sec6-0300060518761304}
-------------------------------

*VDR Tru*9I (rs757343) genotyping was performed using polymerase chain reaction-restriction fragment length polymorphism analysis. The forward primer F: 5'-GCAGGGTACAAAACTTTGGAG-3\' and the reverse primer R: 5'-CCTCATCACCGACATCATGTC-3\' were used^[@bibr26-0300060518761304]^ to amplify the isolated DNA. Amplification was performed using a thermal cycler (Veriti; Applied Biosystems, Foster City, CA, USA) in a final reaction volume (50 µL) containing 25 µL of 2X GoTaq Green Master Mix (Promega, Madison, WI, USA), 4 µL of 12 pmol of both primers, 5 µL of DNA, and 12 µL of nuclease-free water. Polymerase chain reaction analysis was performed as follows: 94°C, initial denaturation (5 minutes); 40 cycles of denaturation at 94°C (30 s); annealing at 59°C (30 s), and extension at 72°C (30 s). The final extension was performed at 72°C for 7 minutes. The 177-bp amplicons were digested using 5 units of Mse1 (37°C for 1 hour). Amplicons and restriction fragment length polymorphism fragments, which were separated using 2.5% agarose gel electrophoresis, were detected using ethidium bromide and visualized using a ChemiDoc-It2 imaging system with VisionWorks LS Analysis Software (version 7.1) (UVP, Cambridge, UK). The results were coded as U-u, where the Upper case letter is denoted as the absence and lowercase letter is designated as the presence of the restriction site, respectively. The call and concordance rates of the *VDR* genotypes were 98% and 100%, respectively. The accuracy of the genotypes was determined by subjecting samples ( 15 cases and 15 controls) to nucleotide sequence analysis.

Data analysis {#sec7-0300060518761304}
-------------

Statistical analysis was performed using SPSS software version 22 (IBM Corporation, Armonk, NY, USA) with significance indicated by *P* \< 0.05. The Shapiro--Wilk and Kolmogorov--Smirnov tests were used to determine whether the variables were normally distributed. The goodness-of-fit (χ^2^) test was used to test whether the controls exhibited Hardy--Weinberg equilibrium to determine deviation of their genotype distribution. Comparisons between groups of *VDR Tru*9I genotypic and allelic distributions were calculated using Person's χ^2^ test. Odds ratios (ORs) along with 95% CIs were determined using binary and multinomial logistic regression analysis of the *Tru*9I SNP to determine the risk of BC. The significance of ORs was determined using Wald's statistics and defined as *P* \< 0.05.

Results {#sec8-0300060518761304}
=======

Characteristics of patients with BC {#sec9-0300060518761304}
-----------------------------------

Patients' characteristics are presented in [Table 1](#table1-0300060518761304){ref-type="table"}, which shows that the parameters were not normally distributed among patients according to the Shapiro--Wilk and Kolmogorov--Smirnov tests (*P* \< 0.01).

###### 

Characteristics of patients with BC (N = 228).

![](10.1177_0300060518761304-table1)

  Characteristics                                   Patients
  ------------------------------------------------- ------------
  Affected area                                     
   Right\*                                          123 (53.9)
   Left\*                                           99 (43.2)
   Both\*                                           6 (2.6)
  Types of BC                                       
   Invasive ductal carcinoma (IDC)\*                197 (93.4)
   Invasive lobular carcinoma (ILC)\*               13 (5.7)
   Ductal carcinoma in situ (DCIS)\*                6 (2.6)
   Others\*                                         12 (5.2)
  Grades of BC                                      
   I\*                                              6 (2.6)
   II\*                                             164 (71.9)
   III\*                                            45 (19.7)
   IV\*                                             7 (3)
   Both II &III\*                                   2 (1.3)
   None\*                                           4 (1.7)
  Immunohistochemical classification                
   Estrogen receptor status                         
   Positive (0 to +9)\*                             126 (55.3)
   Negative (−1 to −2)\*                            34 (14.9)
   Unknown                                          68 (29.8)
  Progesterone receptor status                      
   Positive (0 to +8)\*                             114 (5)
   Negative (−1 to −2)\*                            38 (16.6)
   Unknown                                          76 (33.33)
  Human epidermal growth factor receptor 2 status   
   Positive (0 to +3)\*                             98 (42.9)
   Negative (−1 to −2)\*                            20 (8.7)
   Unknown                                          110 (48.2)
  TNM classification                                
  (For invasive cases only)                         
  Size of primary tumor (T stage)                   
   Tx\*                                             2 (0.8)
   Tis\*                                            4 (1.7)
   T1\*                                             0 (0)
   T2\*                                             35 (15.3)
   T3\*                                             31 (13.5)
   T4\*                                             26 (11.4)
   No involvement\*                                 199 (56.5)
  Metastasis to regional lymph node                 
  (N stage)                                         
   Nx\*                                             6 (2.6)
   N0\*                                             23 (10)
   N1\*                                             36 (15.7)
   N2\*                                             19 (8.3)
   N3\*                                             15 (6.5)
   No involvement\*                                 129 (56.5)
  Distant metastasis (M stage)                      
   Mx\*                                             39 (17.1)
   M0\*                                             48 (21.0)
   M1\*                                             12 (5.2)
   Unknown                                          129 (56.5)

BC, breast cancer. \*Statistically significant difference (*P* \< 0.05, Shapiro--Wilk or Kolmogorov--Smirnov tests).

Association of the VDR Tru9I SNP with BC {#sec10-0300060518761304}
----------------------------------------

The genotype distributions of *Tru*9I among patients (228/228) and healthy controls (497/503) are presented in [Table 2](#table2-0300060518761304){ref-type="table"}. The distribution of *Tru*9I in the control population did not deviate (χ^2^ = 0.416, *P* \> 0.05) from the Hardy--Weinberg equilibrium. There was no significant difference (χ^2^ = 0.238) between the *VDR Tru*9I genotype among patients and controls. However, an 11.2% increase in OR (1.112; 95% CI, 0.202--6.125) was observed among 'uu' carriers compared with 'UU and Uu' carriers. After adjusting for age, the *VDR Tru*9I 'uu' genotype exhibited a 14.1% increase in the OR (1.141; 95% CI, 0.206--6.317) ([Table 2](#table2-0300060518761304){ref-type="table"}).

###### 

*VDR Tru*9I genotype frequencies and associations with the risk of premenopausal BC.

![](10.1177_0300060518761304-table2)

  ---------------------------------------------------------------------------------------------------------------------------------------------------------
  Genotypes   Alternate designation   BC cases\    Controls\    Χ^2^                   *P* value              UOR (95% CI)           AOR (95% CI)
                                      n (%)        n (%)                                                                             
  ----------- ----------------------- ------------ ------------ ---------------------- ---------------------- ---------------------- ----------------------
  GG          UU                      179 (78.5)   398 (80)     0.238                  0.888                  Ref                    Ref

  GA          Uu                      47 (20.6)    95 (19.1)    1.1 (0.744--1.627)     1.085 (0.731--1.611)                          

  AA          uu                      2 (0.88)     4 (0.8)      1.112 (0.202--6.125)   1.141 (0.206--6.317)                          

  Total                               228          497                                                                               

  GG          UU                      179 (78.5)   398 (80)                                                   Ref                    Ref

  GA+AA       Uu+uu                   49 (21.4)    99 (19.6)                                                  1.101 (0.749--1.617)   1.087 (0.737--1.604)

  Total                               228          497                                                                               

  G allele    U allele                405 (88.8)   891 (89.6)   0.223                  0.637                  Ref                    Ref

  A allele    u allele                51 (11.1)    103 (10.3)   1.089 (0.763--1.554)   1.086 (0.76--1.55)                            

  Total                               456          994                                                                               
  ---------------------------------------------------------------------------------------------------------------------------------------------------------

DNA was amplified from 228/228 patients' samples and 497/503 control subjects' samples. BC, breast cancer; UOR, unadjusted odds ratio; AOR, odds ratio adjusted for age and time of blood collection, CI, confidence interval.

Association of the VDR Tru9I SNP with specific pathological characteristics of patients with BC {#sec11-0300060518761304}
-----------------------------------------------------------------------------------------------

We next investigated the association of the *VDR Tru*9I SNP with BC risk through immunohistochemical subtyping of BC tissues and TNM classification ([Table 3](#table3-0300060518761304){ref-type="table"}). A direct association with risk of BC was found for at least one 'u' allele, which was more evident and significant for G-IV stage carcinoma (OR, 5.36; 95% CI, 1.181--24.338).

###### 

Associations of the *VDR Tru*9I single nucleotide polymorphism and risk of premenopausal BC according to the immunohistochemical and pathological characteristics of patients with BC.

![](10.1177_0300060518761304-table3)

  -----------------------------------------------------------------------------------------------------------
                                            *Tru*9I genotype                 
  ----------------------------------------- ------------------ ----- ------- --------------------------------
  Types of BC                                                                

   IDC                                      152/398            Ref   45/99   1.19 (0.799--1.774)

   ILC                                      13/398             Ref   0/99    1.67 × 10^−9^\
                                                                             (1.67 × 10^−9^--1.67 × 10^−9^)

   DCIS                                     5/398              Ref   1/99    0.804 (0.93--6.96)

   Other                                    9/398              Ref   3/99    1.34 (0.356--5.042)

  Grades of BC                                                               

   I                                        5/398              Ref   1/99    0.804 (0.093--6.96)

   II                                       131/398            Ref   33/99   1.02 (0.66--1.578)

   III                                      35/398             Ref   10/99   1.149 (0.55--2.399)

   IV                                       3/398              Ref   4/99    5.36 (1.181--24.338)\*

   II & III                                 2/398              Ref   0/99    12 × 10^−9^\
                                                                             (12 × 10^−9^--12 × 10^−9^)

   Unknown                                  3/398              Ref   1/99    1.34 (0.138--13.02)

  Immunohistochemical classification                                         

  Estrogen receptor status                                                   

   Positive (0 to +9)                       103/398            Ref   23/99   0.898 (0.543--1.484)

   Negative (−1 to −2)                      25/398             Ref   9/99    1.447 (0.655--3.199)

   None                                     51/398             Ref   17/99   1.34 (0.742--2.421)

  Progesterone receptor status                                               

   Positive (0 to +8)                       92/398             Ref   22/99   0.961 (0.575--1.608)

   Positive (−1 to −2)                      30/398             Ref   8/99    1.072 (0.477--2.411)

   None                                     57/398             Ref   19/99   1.34 (0.762--2.355)

  Human epidermal growth\                                                    
  factor receptor 2 status                                                   

   Positive (0 to +3)                       78/398             Ref   20/99   1.031 (0.602--1.766)

   Negative (−1 to −2)                      18/398             Ref   2/99    0.447 (0.102--1.957)

   None                                     83/398             Ref   27/99   1.308 (0.804--2.128)

  TNM classification (For invasive cases)                                    

  Size of primary tumor (T stage)                                            

   Tx                                       1/398              Ref   1/99    4.681 (0.277--79.215)

   Tis                                      3/398              Ref   1/99    1.281 (0.13--12.598)

   T1                                       0/398              Ref   0/99    NC

   T2                                       27/398             Ref   9/99    1.412 (0.639--3.121)

   T3                                       25/398             Ref   6/99    0.896 (0.354--2.267)

   T4                                       23/398             Ref   3/99    0.521 (0.152--1.783)

   No involvement                           100/398            Ref   29/99   1.135 (0.706--1.823)

  Metastasize to regional\                                                   
  lymph node (N stage)                                                       

   Nx                                       4/398              Ref   2/99    1.821 (0.325--10.218)

   N0                                       20/398             Ref   3/99    0.593 (0.172--2.048)

   N1                                       25/398             Ref   11/99   1.796 (0.847--3.806)

   N2                                       16/398             Ref   3/99    0.737 (0.209--2.598)

   N3                                       14/398             Ref   1/99    0.297 (0.038--2.304)

   No involvement                           100/398            Ref   29/99   1.134 (0.706--1.822)

  Distant metastasis (M stage)                                               

   Mx                                       29/398                   10/99   1.386 (0.654--2.94)

   M0                                       39/398             Ref   9/99    0.928 (0.435--1.979)

   M1                                       11/398             Ref   1/99    0.365 (0.047--2.864)

   No involvement                           100/398            Ref   29/99   1.166 (0.73--1.862)
  -----------------------------------------------------------------------------------------------------------

BC, breast cancer; CI, confidence interval; OR, odds ratio. *VDR Tru*9I "Uu" and "uu" genotypes were combined, because there were very few subjects with "uu." ORs were calculated using multinomial logistic regression analysis adjusted for age and time of blood collection. \**P* \< 0.05.

Relationship of the *VDR Tru*9I SNP and risk factors associated with BC {#sec12-0300060518761304}
-----------------------------------------------------------------------

The possible relationship of the *Tru*9I SNP and other contributing factors to the risk of BC are presented in [Table 4](#table4-0300060518761304){ref-type="table"}. Those with the mutant (Uu+uu) genotype along with Sindhi and Baluchi ethnicity and marital age greater than 20 years were at significantly increased risk of developing BC; however, there were no significant associations with other contributing factors and BC.

###### 

Combined associations of the *VDR Tru*9I single nucleotide polymorphism and factors contributing to the risk of premenopausal BC.

![](10.1177_0300060518761304-table4)

  --------------------------------------------------------------------------------------------------------------------------------------------------
  BC risk factors                      Combined   UU                         Uu+uu                                        
  ------------------------------------ ---------- -------------------------- --------- -------------------------- ------- --------------------------
  Age (years)\#                                                                                                           

   20--26 (Younger)                    20/58      Ref                        16/51     Ref                        4/5     Ref

   27--33                              34/78      1.264 (0.661--2.418)       23/53     1.383 (0.667--2.914)       11/23   0.598 (0.134--2.675)

   34--40                              110/225    1.418 (0.812--2.475)       83/179    1.478 (0.796--2.745)       27/44   0.767 (0.189--3.109)

   41--45 (Older)                      64/142     1.307 (0.726--2.352)       57/115    1.58 (0.829--3.012)        7/27    0.324 (0.068--1.535)

   Total                               228/503                               179/398                              49/99   

  Ethnicity/Race                                                                                                          

   Urdu-Speaking                       94/252     Ref                        78/199    Ref                        16/51   Ref

   Sindhi                              41/12      9.41 (4.719--18.767)\*     29/9      8.456 (3.809--18.772)\*    12/3    14.934 (3.573--62.418)\*

   Panjabi                             20/104     0.522 (0.305--0.891)\*     16/86     0.493 (0.272--0.897)\*     4/17    0.675 (0.193--2.335)

   Pukhtoon                            18/47      0.996 (0.549--1.806)       15/39     0.946 (0.492--1.821)       3/8     0.97 (0.22--4.283)

   Baluchi                             19/4       12.926 (4.265--39.171)\*   12/3.     10.875 (2.963--39.908)\*   7/1     19.323 (2.15--173.641)\*

   Others                              36/84      1.17 (0.738--1.854)        29/62     1.188 (0.709--1.992)       7/19    1.179 (0.408--3.41)

   Total                               228/503                               179/398                              49/99   

  Marital status                                                                                                          

   Yes                                 208/363    Ref                        162/286   Ref                        45/75   Ref

   No                                  20/140     0.139 (0.071--0.273)\*     16/112    0.15 (0.071--0.318)\*      4/24.   0.111 (0.024--0.524)\*

   Total                               228/503                               179/398                              49/99   

  Marital age (years)                                                                                                     

   \<20                                105/244    Ref                        84/186    Ref                        21/56   Ref

   20 to 30                            95/117     3.343 (2.157--5.18)\*      71/98     2.48 (1.525--4.033)\*      24/19   10.645 (3.473--32.623)\*

   \>30                                8/2.       20.996 (4.15--106.236)\*   8/2.      15.914 (3.138--80.698)\*   0/0     NC

   Total                               208/363                               163/286                              45/75   

  Parity                                                                                                                  

   Parous                              191/342    Ref                        149/267   Ref                        40/71   Ref

   Nulliparous                         37/161     0.347 (0.216--0.557)\*     30/131    0.366 (0.216--0.619)\*     9/28    0.395 (0.145--1.071)

   Total                               228/503                               179/398                              45/99   

  Age at first child birth (years)                                                                                        

   Below 20                            49/63      Ref                        41/55     Ref                        8/8     Ref

   20 to 24                            81/118     0.528 (0.33--0.845)\*      64/87     0.515 (0.302--0.879)\*     17/30   0.582 (0.208--1.627)

   25 to 29                            39/115     0.621 (0.328--1.179)       30/88     0.458 (0.215--0.977)\*     9/26    1.533 (0.41--5.731)

   \>29                                17/43      1.218 (0.753--1.969)       11/36     1.086 (0.639--1.846)       6/7     2.006 (0.604--6.661)

   Total                               186/339                               146/266                              40/71   

  History of breast feeding                                                                                               

   Yes                                 186/339    Ref                        146/266   Ref                        40/71   Ref

   No                                  22/24      1.674 (0.901--3.107)       17/20     1.54 (0.773--3.068)        5/4     2.269 (0.528--9.748)

   Total                               208/363                               163/286                              45/75   

  Age at menarche (years)                                                                                                 

   12 to 14                            186/423    Ref                        148/334   Ref                        38/83   Ref

   \>14                                28/45      0.913 (0.479--1.74)        13/29     0.995 (0.5--1.978)         1/6     0.306 (0.035--2.662)

   \<12                                14/35      1.389 (0.838--2.303)       18/35     1.111 (0.606--2.035)       10/10   2.567 (0.946--6.966)

   Total                               228/503                               179/398                              49/99   

  Use of hormone replacement therapy                                                                                      

   No                                  209/481    Ref                        168/382   Ref                        41/93   Ref

   Yes                                 19/22      1.954 (1.034--3.691)\*     11/16.    1.547 (0.702--3.412)       8/6     3.114 (0.99--9.798)

   Total                               228/503                               179/398                              49/99   

  Use of oral contraceptive                                                                                               

   No                                  197/454    Ref                        155/361   Ref                        42/87   Ref

   Yes                                 31/49      1.473 (0.91--2.383)        24/37     1.521 (0.878--2.635)       7/12    1.17 (0.423--3.234)

   Total                               228/503                               179/398                              49/99   

  Waist to hip ratio                                                                                                      

   Good (\<0.8)                        27/92      Ref                        20/71     Ref                        7/19    Ref

   Average (0.8--0.85)                 15/173     0.296 (0.15--0.585)\*      12/134    0.317 (0.146--0.685)\*     3/37    0.252 (0.057--1.12)

   High (\>0.85)                       186/238    2.687 (1.672--4.317)\*     147/193   2.727 (1.58--4.707)\*      39/43   2.568 (0.949--6.944)

   Total                               228/503                               179/398                              49/99   

  BMI (kg/m^2^)                                                                                                           

   Normal/healthy\                     56/157     Ref                        43/127    Ref                        13/29   Ref
  weight (18.6--23)                                                                                                       

   Underweight (\>18.5)                22/64      0.966 (0.544--1.717)       19/48     1.196 (0.633--2.261)       3/14    0.383 (0.09--1.637)

   Overweight (23.1--27)               79/158     1.381 (0.909--2.097)       63/132    1.374 (0.858--2.2)         16/23   1.689 (0.654--4.364)

   Obese (\>27)                        71/124     1.589 (1.028--2.456)       54/91     1.708 (1.036--2.815)\*     17/33   1.183 (0.474--2.953)

   Total                               228/503                               179/398                              49/99   

  Family history of BC                                                                                                    

   No                                  191/455                               149/361   Ref                        42/88   Ref

   Yes                                 37/48      1.83 (1.153--2.906)\*      30/37     1.947 (1.156--3.28)\*      7//11   1.348 (0.473--3.841)

   Total                               228/503                               179/398                              49/99   
  --------------------------------------------------------------------------------------------------------------------------------------------------

*VDR Tru9I* "Uu" and "uu" genotypes were combined because there were very few subjects in the "uu" category. DNA was amplified from 228/228 patients' samples and 497/503 control subjects' samples. ORs were adjusted for age and time of blood collection. \**P* \<0.05.

\#Crude/unadjusted ORs for age were calculated. BC, breast cancer; BMI, body mass index; NC, not calculated, OR, odds ratio.

Nine models of contributing factors were prepared in which the *Tru*9I genotype was adjusted by sequentially adding individual contributing factors (Appendix 1). This analysis shows that the *Tru*9I 'uu' genotype in model 8 significantly increased the risk of BC (OR, 1.288; 95% CI, 0.16--10.398).

Discussion {#sec13-0300060518761304}
==========

Among Asian countries, Pakistan has the highest incidence of BC,^[@bibr27-0300060518761304]^ which is a heterogeneous group of diseases associated with various risk factors. The most common risk factor is exposure to endogenous hormones such as estradiol.^[@bibr28-0300060518761304]^ Approximately 15% of BC is caused by genetic changes,^[@bibr29-0300060518761304]^ including those associated with high penetrance genes such as *BRCA* 1/2,^[@bibr30-0300060518761304]^ and low-to-moderate penetrance genes such as checkpoint kinase-2 (*CHEK*2) and *VDR*.^[@bibr20-0300060518761304],[@bibr31-0300060518761304]^ VDR contributes to the prevention of BC, and the vitamin D/VDR complex induces apoptosis, reduces angiogenesis, proliferation, and invasion and increases cell differentiation.^[@bibr32-0300060518761304]^

Evidence indicates that the VDR mediates most of the activities of vitamin D. Analyses of common *VDR* SNPs (*Fok*1, *Bsm*1, *Apa*1, *Taq*1, and *Poly*-A) show associations between *VDR* SNPs and BC, although the results are inconsistent among different types of exposure.^[@bibr20-0300060518761304],[@bibr22-0300060518761304],[@bibr33-0300060518761304],[@bibr34-0300060518761304]^ The *Fok*1 'ff' genotype may increase the risk of BC.^[@bibr35-0300060518761304],[@bibr36-0300060518761304]^ However, evidence suggests that *Fok*1 significantly correlates with human epidermal growth factor receptor 2 status^[@bibr20-0300060518761304]^ and is significantly associated with estrogen receptor status of patients with BC.^[@bibr37-0300060518761304]^ One study shows that the *Bsm*1 'b' allele is associated with risk of BC;^[@bibr20-0300060518761304]^ although another study reports the opposite results.^[@bibr22-0300060518761304]^ To our knowledge, the present study is the first to determine the association of the low penetrance *VDR Tru*9I polymorphism with premenopausal BC. The *VDR Tru*9I is caused by an A to G substitution that was first identified in 2000.^[@bibr38-0300060518761304]^ *VDR Tru*9I resides in intron 8, +443-bp from the end of exon 8, and may be involved in the regulation of gene expression through its affect on enhancer affinity and target area.^[@bibr39-0300060518761304]^

The present study shows that the *Tru*9I mutant 'uu' genotype was associated with an increased risk of developing premenopausal BC. There are few association studies of *Tru*9I in other diseases such as coronary heart disease (CHD), colorectal adenoma, and prostate cancer.^[@bibr26-0300060518761304],[@bibr39-0300060518761304],[@bibr40-0300060518761304]^ However, *Tru*9I is not associated with CHD^[@bibr39-0300060518761304]^ and prostate cancer^[@bibr40-0300060518761304]^ among the Chinese Han population, whereas *Tru*9I lowers the risk of colorectal carcinoma among women living in North Carolina.^[@bibr26-0300060518761304]^ We show further that mutant *Tru*9I may be associated with the development of Grade IV carcinoma, whereas another study shows the opposite relationship with colorectal adenoma, which is more pronounced for multiple, larger, and sessile adenomas, and perhaps with dysplasia.^[@bibr26-0300060518761304]^

This study has certain limitations. First, the sample size was relatively small. Large-scale studies are therefore required to support our conclusions. Second, we did not study environmental factors including diet and lifestyle, which may modify the association between the *VDR Tru*9I polymorphism and BC. Finally, other *VDR* SNPs and serum vitamin D levels were not studied. However, further research is required to confirm our findings and explore the possible mechanisms of BC underlying the association of *VDR Tru*9I with oncogenesis to facilitate the development of more effective treatment.

We conclude that the *VDR Tru*9I 'uu' genotype may predict a high risk for premenopausal BC.
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